Cartesian Therapeutics (RNAC) Receivables - Other: 2020-2024
Historic Receivables - Other for Cartesian Therapeutics (RNAC) over the last 3 years, with Sep 2024 value amounting to $980,000.
- Cartesian Therapeutics' Receivables - Other fell 47.73% to $980,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $980,000, marking a year-over-year decrease of 47.73%. This contributed to the annual value of $3.0 million for FY2023, which is 5.72% down from last year.
- As of Q3 2024, Cartesian Therapeutics' Receivables - Other stood at $980,000, which was down 71.77% from $3.5 million recorded in Q2 2024.
- Cartesian Therapeutics' Receivables - Other's 5-year high stood at $3.5 million during Q2 2024, with a 5-year trough of $980,000 in Q3 2024.
- Moreover, its 3-year median value for Receivables - Other was $2.1 million (2023), whereas its average is $2.2 million.
- Over the last 5 years, Cartesian Therapeutics' Receivables - Other had its largest YoY gain of 229.10% in 2024, and its largest YoY loss of 47.73% in 2024.
- Cartesian Therapeutics' Receivables - Other (Quarterly) stood at $1.4 million in 2020, then tumbled by 33.33% to $1.0 million in 2021, then reached $3.2 million in 2022, then decreased by 5.72% to $3.0 million in 2023, then tumbled by 47.73% to $980,000 in 2024.
- Its Receivables - Other stands at $980,000 for Q3 2024, versus $3.5 million for Q2 2024 and $2.4 million for Q1 2024.